Enjoy complimentary customisation on priority with our Enterprise License!
The krabbe disease treatment market size is forecast to increase by USD 405.4 million and is estimated to grow at a CAGR of 7.08% between 2023 and 2028. Introducing Biotique, a leading biopharmaceutical company specializing in the research, development, and commercialization of innovative therapeutics. Our key offering is a portfolio of drugs with special designations, addressing unmet clinical needs in various therapeutic areas. II. Our commitment to innovation is rooted in a deep understanding of the scientific community and the unmet clinical needs that patients face. We prioritize researching and developing drugs that address these needs, often in areas where traditional treatments have fallen short. III. Biotique's dedication to advancing healthcare extends beyond our research and development efforts. We recognize the cultural and societal implications of certain medical practices, such as consanguineous marriage, and strive to provide solutions that respect and accommodate these practices while addressing the associated health concerns. IV. Our team of experts collaborates closely with healthcare professionals, regulatory agencies, and patient advocacy groups to ensure our drugs are safe, effective, and accessible to those who need them most. Together, we are making a difference in the lives of patients around the world.
For More Highlights About this Report, Request Free Sample
Krabbe Disease, also known as Globoid Cell Leukodystrophy, is a rare and severe genetic disorder that affects the Central Nervous System (CNS), particularly the myelin sheath of nerve cells. This condition can lead to various symptoms such as vomiting, feeding difficulties, fever, muscle spasms, seizures, imbalances, loss of hearing, and vision problems in children. The market is witnessing significant growth due to the increasing number of diagnosed cases and the need for effective therapies. Currently, supportive care is the primary treatment approach, which includes managing symptoms through various methods such as imaging scans, nerve conduction studies, and eye examinations. Healthcare professionals use anticonvulsant medications to manage seizures and provide nutritional support to manage feeding difficulties. However, novel treatments such as stem cell transplants and gene therapies are under development and show promising results. These therapies aim to replace the missing or defective enzyme and promote the production of healthy myelin sheaths. Patient advocacy groups are playing a crucial role in raising awareness and funding for research and development of new Krabbe Disease treatments. Medical science continues to explore innovative therapies to improve the quality of life and potentially cure this debilitating disorder. Caregivers and families of affected individuals are eagerly awaiting the availability of these new treatments. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Special drug designation is notably driving market growth. Krabbe disease, a rare genetic ailment, presents a significant market opportunity for novel treatments and therapies. The therapy market for Krabbe disease is driven by various factors, including government funding for research, the growing patient pool, and the assignment of special drug designations for safe and effective treatments by regulatory bodies like the Food and Drug Administration (FDA).
Moreover, the priority review program offered by the FDA facilitates fast drug approvals, enabling sponsors to obtain priority review vouchers upon approval of a biologic or drug for a rare pediatric disease. Thus, such factors are driving the growth of the market during the forecast period.
Emergence of pharmacological chaperone therapy is the key trend in the market. Krabbe disease, a rare genetic ailment, is characterized by a missense mutation in the GLC enzyme, which affects enzyme folding and hinders its transportation to the lysosome. This results in insufficient quantities of the enzyme at the site of action, leading to the accumulation of substrate in the central nervous system.
Moreover, traditional therapies, such as anticonvulsant medication and physical therapy, have limited efficacy due to the unique nature of Krabbe disease. Government funding, patient advocacy groups, and research centers are actively investing in the development of novel treatments for this condition. Thus, such trends will shape the growth of the market during the forecast period.
Limited patient pool for clinical trials is the major challenge that affects the growth of the market. Krabbe Disease, a rare genetic ailment, poses unique challenges in the development and treatment market. The small patient pool and limited availability of standard tools for diagnosis, such as eye inspection, hinder the progress of therapies in this market.
Moreover, government funding and collaborations between hospitals and clinics, research centers, laboratories, and medical science institutions play a crucial role in advancing research and care for Krabbe Disease. Patient advocacy groups are instrumental in raising awareness and promoting the development of novel treatments, including anticonvulsant medications and gene therapies. Hence, the above factors will impede the growth of the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc: The company offers Tridone as anticonvulsants drugs for the treatment krabbe disease.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The anticonvulsants segment is estimated to witness significant growth during the forecast period. Krabbe disease, also known as Globoid Cell Leukodystrophy, is a rare and severe genetic disorder that affects the Central Nervous System (CNS) and primarily impacts the myelin sheath of nerve cells in the brain. This condition can manifest in both infantile and late-onset forms, causing various symptoms such as vomiting, feeding difficulties, fever, muscle spasms, seizures, imbalances, loss of hearing, loss of sight, restricted muscles, trouble walking, visual loss, and muscle weakness.
Get a glance at the market share of various regions Download the PDF Sample
The anticonvulsants segment was the largest segment and valued at USD 320 million in 2018. Healthcare professionals often diagnose Krabbe disease through a combination of clinical examination, imaging scans, nerve conduction studies, eye examination, and genetic testing. Currently, there is no cure for Krabbe disease, and treatment primarily focuses on managing symptoms and providing supportive care. Anticonvulsant agents and muscle relaxer drugs are commonly used to treat seizures and muscle spasms. Hence, such factors are fuelling the segment during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 31% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Krabbe Disease, also known as Globoid Cell Leukodystrophy, is a genetic disorder affecting the Central Nervous System (CNS) and primarily the myelin sheath of nerve cells. This condition results in the degeneration of nerve fibers in the brain and throughout the body. Symptoms in infants include vomiting, feeding difficulties, fever, muscle spasms, seizures, imbalances, loss of hearing, loss of sight, restricted muscles, trouble walking, visual loss, and muscle weakness. For diagnosis, healthcare professionals utilize imaging scans, nerve conduction studies, eye examinations, and genetic testing. Hence, such factors are driving the market in North America during the forecast period.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Million " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
You may also interested in below market reports:
Krabbe Disease, also known as Globoid Cell Leukodystrophy, is a rare and severe genetic disorder that affects the Central Nervous System (CNS), specifically the myelin sheath of nerve cells. This condition can lead to various neurological symptoms in children, including vomiting, feeding difficulties, fever, muscle spasms, seizures, imbalances, loss of hearing, loss of sight, restricted muscles, trouble walking, visual loss, and muscle weakness.
The market is primarily focused on supportive care and disease management. Healthcare professionals use various diagnostic tools such as imaging scans, nerve conduction studies, eye examinations, and genetic testing to diagnose the condition. Currently, there are no cure-all treatments for Krabbe Disease, and the available treatments include anticonvulsant agents and muscle relaxer drugs for symptomatic relief. Stem cell transplants, including bone marrow transplantation, are being explored as potential treatments for Krabbe Disease. Clinical trials are underway to evaluate the safety and efficacy of biologics and gene technology-based therapies. The market is expected to grow as new treatments and therapies enter the clinical development pipeline. The market is segmented into infantile and late-onset forms of the disease. The market includes retail pharmacies, e-commerce, and hospital pharmacies as distribution channels. The market is expected to grow due to the increasing number of diagnosed cases and the development of new treatments.
Market Scope |
|
Report Coverage |
Details |
Page number |
145 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.08% |
Market growth 2024-2028 |
USD 405.4 million |
Market structure |
Concentrated |
YoY growth 2023-2024(%) |
6.49 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 31% |
Key countries |
US, Canada, UK, Germany, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Acorda Therapeutics Inc., CENTOGENE NV, GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Novartis AG, Pfizer Inc., Polaryx, Teva Pharmaceutical Industries Ltd., and UCB SA |
Market dynamics |
Parent market analysis, market report, market forecast, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Therapy
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.